Cohort one was curated to maintain an even representation of all BC subtypes, whereas cohort two aimed to mirror the real-world distribution of BC subtypes, inadvertently yielding a greater number of HER2-negative specimens compared to HER2-positive specimens. Here, ERBB2 is linked to breast cancer.